Stay updated with breaking news from Nasdaq Sndx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reiterated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $41.00 price objective on the stock. Other analysts have also issued reports about the stock. StockNews.com upgraded shares of Syndax Pharmaceuticals to a sell rating in […]
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) posted its earnings results on Tuesday. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.01), Briefing.com reports. During the same period in the prior year, the business posted ($0.62) earnings per share. Syndax Pharmaceuticals Price Performance NASDAQ:SNDX traded […]
Algert Global LLC increased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 79.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 456,219 shares of the company’s stock after purchasing an additional 202,588 shares during the period. […]
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) was downgraded by Scotiabank from a “sector outperform” rating to a “sector perform” rating in a note issued to investors on Wednesday, Briefing.com reports. They currently have a $23.00 price objective on the stock, down from their previous price objective of $36.00. Scotiabank’s target price would indicate a […]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) shares traded down 3.8% during trading on Wednesday . The company traded as low as $20.43 and last traded at $20.43. 320,648 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 1,020,577 shares. The stock had previously closed at $21.23. […]